Narrative review highlights tacrolimus's role in managing ocular diseases, suggesting formulation-specific strategies for best outcomes.
Tacrolimus is a practical steroid‑sparing therapy for severe ocular surface inflammation. Priority trials should be formulation‑specific with standardized outcomes and pharmacokinetic endpoints, alongside pediatric safety registries and head‑to‑head comparisons versus cyclosporine 2% and soft steroids.
No takes yet. Share an insight, caveat, or question.
Ali Hendi Alghamdi (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: